Thrivent Financial for Lutherans
BPMC

Thrivent Financial for Lutherans’s Blueprint Medicines BPMC Stock Holding History

Thrivent Financial for Lutherans’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,515
Closed -$277K – 2487
2023
Q3 		$277K Sell
5,515
-9,078
-62% -$485K ﹤0.01% 2320
2023
Q2 		$922K Sell
14,593
-421
-3% -$22.9K ﹤0.01% 1856
2023
Q1 		$675K Hold
15,014
– – ﹤0.01% 2004
2022
Q4 		$658K Buy
15,014
+10,519
+234% +$504K ﹤0.01% 1974
2022
Q3 		$296K Buy
+4,495
New +$289K ﹤0.01% 2233
2022
Q2 		– Sell
-11,545
Closed -$737K – 2422
2022
Q1 		$737K Buy
+11,545
New +$829K ﹤0.01% 2002
2020
Q3 		– Sell
-5,903
Closed -$460K – 2377
2020
Q2 		$460K Hold
5,903
– – ﹤0.01% 1944
2020
Q1 		$345K Buy
+5,903
New +$380K ﹤0.01% 1912

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Thrivent Financial for Lutherans's BPMC Position: Q4 2023 in Review

Thrivent Financial for Lutherans sold out of Blueprint Medicines (BPMC) in Q4 2023, closing a stake of 5,515 shares — an estimated $277K sold.

Thrivent Financial for Lutherans first reported a position in BPMC in Q1 2020 and held it in 8 quarters. The position peaked at $922K in Q2 2023. 259 funds tracked by Wall St. Rank hold BPMC as of Q4 2023.

  • Thrivent Financial for Lutherans reported no remaining Blueprint Medicines position as of Q4 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 5,515 Blueprint Medicines shares in Q4 2023, an estimated $277K.
  • Thrivent Financial for Lutherans first reported a position in Blueprint Medicines in Q1 2020 and held it in 8 quarters.
  • Thrivent Financial for Lutherans's Blueprint Medicines position peaked at $922K in Q2 2023.
  • 259 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2023, filed 14 Feb 2024.